GlaxoSmithKline Stock – reports success in virus vaccine
- Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported “strong immune responses” in early tests of their COVID-19 vaccine, raising hopes it could join the fight against the pandemic.
- The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK’s adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.
- The experimental vaccine “achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers,” it said in a statement.
- “A global pivotal Phase 3 study is expected to start in the coming weeks.”
- The Phase 2 interim results showed 95% to 100% seroconversion following the second injection in all age groups (18 to 95 years old) across all doses, with acceptable tolerability and no safety concerns.
- A single dose generated high neutralizing antibody levels in participants with evidence of prior SARS-CoV-2 infection, suggesting strong potential for development as a booster vaccine.
- The company plans to initiate a global Phase 3 study with the 10µg dose in more than 35,000 adult participants.
- It will assess the efficacy of two vaccine formulations, including the D614 (Wuhan) and B.1.351 (South African) variants.
- In parallel, the companies intend to conduct booster studies with various variant formulations to assess if a lower vaccine dose generates a strong booster response regardless of the initial vaccine platform received.
- The vaccine’s approval is expected in the fourth quarter of 2021, subject to regulations and Phase 3 outcome.
- price Action: GSK shares are down 0.15% at $39.02, and SNY shares are up 0.42% are at $52.96 during the premarket session on the last check Monday.
© 2021 Fintech Zoom.com. Fintech Zoom does not provide investment advice. All rights reserved.